142 related articles for article (PubMed ID: 20947547)
21. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
[TBL] [Abstract][Full Text] [Related]
22. Longterm followup of childhood lupus nephritis.
Hagelberg S; Lee Y; Bargman J; Mah G; Schneider R; Laskin C; Eddy A; Gladman D; Urowitz M; Hebert D; Silverman E
J Rheumatol; 2002 Dec; 29(12):2635-42. PubMed ID: 12465165
[TBL] [Abstract][Full Text] [Related]
23. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
[TBL] [Abstract][Full Text] [Related]
24. Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking.
Ward MM; Studenski S
Arch Intern Med; 1992 Oct; 152(10):2082-8. PubMed ID: 1417382
[TBL] [Abstract][Full Text] [Related]
25. Treatment of proliferative lupus nephritis--a critical approach.
Buhaescu I; Covic A; Deray G
Semin Arthritis Rheum; 2007 Feb; 36(4):224-37. PubMed ID: 17067659
[TBL] [Abstract][Full Text] [Related]
26. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
[TBL] [Abstract][Full Text] [Related]
27. Lupus and its management.
Fagundus DM; Leroy EC
J S C Med Assoc; 1993 Nov; 89(11):516-24. PubMed ID: 8258968
[TBL] [Abstract][Full Text] [Related]
28. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Takada K; Arefayene M; Desta Z; Yarboro CH; Boumpas DT; Balow JE; Flockhart DA; Illei GG
Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological profile of renal changes in systemic lupus erythematosus.
Das SK; Ray A; Jana CK
J Indian Med Assoc; 2010 Nov; 108(11):761-3. PubMed ID: 21510575
[TBL] [Abstract][Full Text] [Related]
30. [Lupus nephritis].
Morović-Vergles J; Salamon L
Reumatizam; 2009; 56(2):34-40. PubMed ID: 20429260
[TBL] [Abstract][Full Text] [Related]
31. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
[TBL] [Abstract][Full Text] [Related]
32. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.
Szeto CC; Kwan BC; Lai FM; Tam LS; Li EK; Chow KM; Gang W; Li PK
Rheumatology (Oxford); 2008 Nov; 47(11):1678-81. PubMed ID: 18753192
[TBL] [Abstract][Full Text] [Related]
33. Diffuse alveolar hemorrhage in systemic lupus erythematosus: a retrospective study in China.
Shen M; Zeng X; Tian X; Zhang F; Zeng X; Zhang X; Xu W
Lupus; 2010 Oct; 19(11):1326-30. PubMed ID: 20647253
[TBL] [Abstract][Full Text] [Related]
34. Clinical approach to lupus nephritis: recent advances.
Molino C; Fabbian F; Longhini C
Eur J Intern Med; 2009 Sep; 20(5):447-53. PubMed ID: 19712841
[TBL] [Abstract][Full Text] [Related]
35. Lupus nephritis.
Agrawal N; Chiang LK; Rifkin IR
Semin Nephrol; 2006 Mar; 26(2):95-104. PubMed ID: 16530602
[TBL] [Abstract][Full Text] [Related]
36. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study.
Valeri A; Radhakrishnan J; Estes D; D'Agati V; Kopelman R; Pernis A; Flis R; Pirani C; Appel GB
Clin Nephrol; 1994 Aug; 42(2):71-8. PubMed ID: 7955581
[TBL] [Abstract][Full Text] [Related]
37. [Significance of serum anti-Clq Ab in evaluation of lupus nephritis activity and its curative effects of pharmacotherapy on lupus nephritis].
Cai XY; Yang XY; Chen XH; Liang LQ; Guan MM; Qin SG; Fu JZ
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(17):1436-9. PubMed ID: 15500738
[TBL] [Abstract][Full Text] [Related]
38. Treatment and renal outcome of lupus nephritis: single center experience.
Go KW; Teo SM
Med J Malaysia; 2006 Oct; 61(4):447-50. PubMed ID: 17243522
[TBL] [Abstract][Full Text] [Related]
39. The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis.
Chan RW; Lai FM; Li EK; Tam LS; Chow KM; Li PK; Szeto CC
Nephrol Dial Transplant; 2006 Jun; 21(6):1534-40. PubMed ID: 16449281
[TBL] [Abstract][Full Text] [Related]
40. Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective.
Hoover PJ; Costenbader KH
Kidney Int; 2016 Sep; 90(3):487-92. PubMed ID: 27344205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
